Home > Report on the risk assessment of 5-(2-aminopropyl)indole in the framework of the Council Decision on new psychoactive substances.

European Monitoring Centre for Drugs and Drug Addiction. (2014) Report on the risk assessment of 5-(2-aminopropyl)indole in the framework of the Council Decision on new psychoactive substances. Luxembourg: Publications Office of the European Union.

[img] PDF (Report on the risk assessment of 5-(2-aminopropyl)indole ) - Published Version
945kB

This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug in the European Union led to an assessment of the health and social risks posed by the substance, and, consequently, its control across the EU Member States.

Table of contents:
• Foreword
• Introduction
• EMCDDA actions on monitoring and responding to new drugs
• EMCDDA–Europol Joint Report on 5-(2-aminopropyl)indole: a summary
• Risk Assessment Report of a new psychoactive substance: 5-(2-aminopropyl)indole
• Annex 1: Technical report on 5-(2-aminopropyl)indole
• Annex 2: Study examining the inhibition of human monoamine oxidase (MAO) by the new psychoactive substance 5-(2-aminopropyl)indole (5-IT)
• Council Implementing Decision 2013/496/EU on subjecting 5-(2-aminopropyl)indole to control measures
• Abbreviations
• Participants of the risk assessment meeting


Item Type
Report
Publication Type
Irish-related, International, Report
Drug Type
New psychoactive substance
Intervention Type
Harm reduction
Date
January 2014
Pages
50 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)
Related (external) link

Repository Staff Only: item control page